ARCUTIS BIOTHERAPEUTICS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$142.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$142.00K, a 235.24% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$470.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $18.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$27.00K, a 103.26% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$37.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$11.00K, a 101.01% decline from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $1.09M.
- ARCUTIS BIOTHERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$831.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$142.00K 10-Q · filed 2026-08-05 | -$612.00K 10-Q · filed 2026-08-05 | -$594.00K derived: sum of 3 quarters · filed 2026-08-05 | -$621.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$470.00K 10-Q · filed 2026-05-06 | -$452.00K derived: sum of 2 quarters · filed 2026-05-06 | -$479.00K derived: sum of 3 quarters · filed 2026-05-06 | -$374.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$9.00K derived: sum of 2 quarters · filed 2026-02-25 | $96.00K derived: sum of 3 quarters · filed 2026-08-05 | -$37.00K 10-K · filed 2026-02-25 |
| 2025-09-30 | -$27.00K 10-Q · filed 2025-10-28 | $78.00K derived: sum of 2 quarters · filed 2026-08-05 | -$55.00K 10-Q · filed 2025-10-28 | -$595.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $105.00K 10-Q · filed 2026-08-05 | -$28.00K 10-Q · filed 2026-08-05 | -$568.00K derived: sum of 3 quarters · filed 2026-08-05 | $259.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$133.00K 10-Q · filed 2026-05-06 | -$673.00K derived: sum of 2 quarters · filed 2026-05-06 | $154.00K derived: sum of 3 quarters · filed 2026-05-06 | -$7.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$540.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $287.00K derived: sum of 2 quarters · filed 2026-02-25 | $126.00K derived: sum of 3 quarters · filed 2026-02-25 | -$11.00K 10-K · filed 2026-02-25 |
| 2024-09-30 | $827.00K 10-Q · filed 2025-10-28 | $666.00K derived: sum of 2 quarters · filed 2025-10-28 | $529.00K 10-Q · filed 2025-10-28 | $717.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$161.00K 10-Q · filed 2025-08-06 | -$298.00K 10-Q · filed 2025-08-06 | -$110.00K derived: sum of 3 quarters · filed 2026-02-25 | -$2.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$137.00K 10-Q · filed 2025-05-06 | $51.00K derived: sum of 2 quarters · filed 2026-02-25 | $159.00K derived: sum of 3 quarters · filed 2026-02-25 | $281.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $296.00K derived: sum of 2 quarters · filed 2026-02-25 | $418.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.09M 10-K · filed 2026-02-25 |
| 2023-09-30 | $108.00K 10-Q · filed 2024-11-06 | $230.00K derived: sum of 2 quarters · filed 2024-11-06 | $902.00K 10-Q · filed 2024-11-06 | $1.41M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $122.00K 10-Q · filed 2024-08-14 | $794.00K 10-Q · filed 2024-08-14 | $1.30M derived: sum of 3 quarters · filed 2025-02-25 | $960.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $672.00K 10-Q · filed 2024-05-14 | $1.18M derived: sum of 2 quarters · filed 2025-02-25 | $838.00K derived: sum of 3 quarters · filed 2025-02-25 | $606.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $166.00K derived: sum of 2 quarters · filed 2025-02-25 | -$66.00K derived: sum of 3 quarters · filed 2025-02-25 | -$831.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | -$344.00K 10-Q · filed 2023-11-03 | -$576.00K derived: sum of 2 quarters · filed 2023-11-03 | -$1.34M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | -$232.00K 10-Q · filed 2023-08-08 | -$997.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$765.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$253.00K 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |